Amendment No 1

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

Amendment No. 1

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 17, 2009

 

 

DAIS ANALYTIC CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

 

New York  

000-53554

   14-760865

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

11552 Prosperous Drive

Odessa, Florida 33556

(Address of principal executive offices) (Zip code)

(727) 375-8484

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Explanatory Note

The Company is filing this amendment No.1 to the Form 8-K, originally filed Tuesday, December 22, 2009, to attach the correct exhibit 4.1 to remove an incorrect reference to Burnham Hill Partners, LLC.

Items 1.01 and 2.03 Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On December 17, 2009, Dais Analytic Corporation (the “Company”) obtained $1,000,000 of financing from Platinum-Montaur Life Sciences (“Platinum-Montaur”) in the form of an unsecured, interest bearing note, due June 17, 2010 (the “Note”). The Note bears interest at 10% per annum.

In connection with the loan, The Company granted Platinum-Montaur the right to participate in subsequent financings of the Company until June 17, 2010 (the “Right of Participation”). The Right of Participation entitles Platinum Montaur the right to participate in subsequent financings up to the unpaid amount of the Note in such applicable subsequent financing. The Company agreed not to incur additional debt exceeding $500,000 during the Term of the Note.

A copy of the Note is attached hereto as exhibit 4.1

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

4.1    Promissory Note, dated December 17, 2009, by the Company in favor of Platinum- Montaur Life Sciences LLC.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  DAIS ANALYTIC CORPORATION
December 22, 2009   By:   LOGO
    Timothy Tangredi
    Chief Executive Officer, President and Chairman